Evoke Pharma ROE 2012-2025 | EVOK
Current and historical return on equity (ROE) values for Evoke Pharma (EVOK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Evoke Pharma ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-09-30 | $-0.01B | $0.01B | -100.00% |
| 2025-06-30 | $-0.01B | $0.01B | -95.24% |
| 2025-03-31 | $0.00B | $0.01B | -80.00% |
| 2024-12-31 | $-0.01B | $0.00B | -117.65% |
| 2024-09-30 | $-0.01B | $0.00B | -342.86% |
| 2024-06-30 | $-0.01B | $0.00B | -1400.00% |
| 2024-03-31 | $-0.01B | 0 | 0.00% |
| 2023-12-31 | $-0.01B | -0 | 3200.00% |
| 2023-09-30 | $-0.01B | $0.00B | -533.33% |
| 2023-06-30 | $-0.01B | $0.00B | -246.15% |
| 2023-03-31 | $-0.01B | $0.01B | -168.42% |
| 2022-12-31 | $-0.01B | $0.01B | -168.42% |
| 2022-09-30 | $-0.01B | $0.01B | -168.42% |
| 2022-06-30 | $-0.01B | $0.01B | -177.78% |
| 2022-03-31 | $-0.01B | $0.00B | -188.24% |
| 2021-12-31 | $-0.01B | $0.01B | -156.52% |
| 2021-09-30 | $-0.01B | $0.00B | -225.00% |
| 2021-06-30 | $-0.01B | $0.00B | -400.00% |
| 2021-03-31 | $-0.01B | $0.00B | -1866.67% |
| 2020-12-31 | $-0.01B | $0.00B | 2600.00% |
| 2020-09-30 | $-0.01B | $0.00B | -960.00% |
| 2020-06-30 | $-0.01B | $0.00B | -400.00% |
| 2020-03-31 | $-0.01B | $0.01B | -155.56% |
| 2019-12-31 | $-0.01B | $0.01B | -155.56% |
| 2019-09-30 | $-0.01B | $0.01B | -177.78% |
| 2019-06-30 | $-0.01B | $0.01B | -177.78% |
| 2019-03-31 | $-0.01B | $0.00B | -188.24% |
| 2018-12-31 | $-0.01B | $0.01B | -177.78% |
| 2018-09-30 | $-0.01B | $0.00B | -150.00% |
| 2018-06-30 | $-0.01B | $0.00B | -276.92% |
| 2018-03-31 | $-0.01B | $0.00B | -240.00% |
| 2017-12-31 | $-0.01B | $0.01B | -252.63% |
| 2017-09-30 | $-0.01B | $0.01B | -266.67% |
| 2017-06-30 | $-0.01B | $0.01B | -200.00% |
| 2017-03-31 | $-0.01B | $0.00B | -346.67% |
| 2016-12-31 | $-0.01B | $0.00B | -550.00% |
| 2016-09-30 | $-0.01B | $0.00B | -685.71% |
| 2016-06-30 | $-0.01B | $0.00B | -685.71% |
| 2016-03-31 | $-0.01B | $0.00B | -369.23% |
| 2015-12-31 | $-0.01B | $0.01B | -288.89% |
| 2015-09-30 | $-0.01B | $0.01B | -216.67% |
| 2015-06-30 | $-0.01B | $0.01B | -180.65% |
| 2015-03-31 | $-0.02B | $0.01B | -142.86% |
| 2014-12-31 | $-0.01B | $0.01B | -103.70% |
| 2014-09-30 | $-0.01B | $0.02B | -78.79% |
| 2014-06-30 | $-0.01B | $0.02B | -49.32% |
| 2014-03-31 | $-0.01B | $0.01B | -35.71% |
| 2013-12-31 | $0.00B | $0.01B | -21.05% |
| 2013-06-30 | $0.00B | $0.00B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |